Searched for
ASTRAZENECA PHARMACEUTICALS AB
Bollywood celebs express concern over Covishield vaccine's side effects: What they saidAstraZeneca's recent disclosure about Covishield's rare but serious side effects has sparked concerns among both medical professionals and ...- Biopharma giant AstraZeneca begins coronavirus dual-use antibody drug trial in UKThe drug known as AZD7442 has the potential to be given as a preventative option for people exposed to the coronavirus, and to treat and pr...
- Glenmark Pharma gets tentative USFDA nod for generic anti-diabetes tabletsGlenmark Pharmaceuticals on Wednesday said it has received tentative approval from the US health regulator for its generic Dapagliflozin an...
- Under Sebi lens, Elliott offloads 6% in AstraZenecaSebi’s deadline to investigate dealings of the Elliott Group with regard to the de-listing of Astra-Zeneca ended on March 11.
- AstraZeneca Pharma rallies over 12% as shareholders approve delistingAt 09:35 a.m.; AstraZeneca Pharma pared some of the intraday gains but was still trading 8 per cent higher at Rs 1198.90.
- AstraZeneca Pharma board approves delisting of company's shares from stock exchangesAstraZeneca Pharma today said its board has approved delisting of the company's shares from bourses, including BSE and the National Stock E...
- AstraZeneca Pharma shares rise 3 per cent on board's approved delisitngShares of AstraZeneca Pharma rose by 3 per cent as its board has approved delisting of the company's shares from bourses like NSE, BSE etc.
- Volatile AstraZeneca Pharma rallies nearly 9% on de-listing plansAstraZeneca surged after it announced that the voluntary de-listing proposal from AstraZeneca Pharma, Sweden will be considered on March 15...
- Astrazeneca stock down over 9% as board defers delisting offerAstrazeneca Pharma's scrip ended the day 9.31 per cent lower at Rs 1,064.35 on the BSE. During the day, the stock tanked 9.85 per cent to R...
- AstraZeneca Pharma plunges 9% as board defers delisting offerAstraZeneca Pharma slipped as much as 8.8 per cent in intraday trade after the Indian arm of Swedish drug maker deferred delisting plans.
- Astrazeneca Pharma shares plunge over 6% ahead of board meetAstrazeneca's stock tanked 5.26 per cent to close at Rs 1,173.65 on the BSE. In intra-day, the stock slumped 8.62 per cent to Rs 1,132.
- AstraZeneca rallies 15%, hits 52-week high ahead of board meet; up 50% in a monthAfter rallying 20 per cent in trade yesterday, AstraZeneca Pharma put up a strong show today ahead of the company's board meet on Wednesday.
- AstraZeneca jumps 20 per cent on delisting planAstraZeneca’s India unit has revived its plan of delisting the co from the stock markets, an announcement that sent company’s shares soarin...
- AstraZeneca up 20% on delisting proposal, locked in upper circuit at Rs 1,110.90AstraZeneca said in the filing before markets opened on Monday that its board received a request from its promoter to initiate a voluntary ...
- AstraZeneca Pharma promoter to sell stake in Indian armAstraZeneca India today said its promoter AstraZeneca Pharmaceuticals AB Sweden plans to offload around 37 lakh shares through offer for sa...
- AstraZeneca to receive over Rs 140 crore grant from promoterAstraZeneca Pharma AB would be provide the first tranche of Rs 74 cr to the Indian firm in the current financial year, it added.
- AstraZeneca Pharma hits 52-week low as promoter likely to reduce stakeAstraZeneca slipped over 11% to hit its 52-week low on reports that its promoter has decided to reduce shareholding.
- 25pc public holding norm has AstraZeneca, Sulzer delistingThe domestic arms of two multinational companies, the drug maker AstraZeneca and process engineering major Sulzer, plan to delist from the ...
- AstraZeneca Pharma to delist from India; shares jump 20 pcAstraZeneca Pharma India today said it will de-list itself from domestic stock exchanges, fueling a jump of 20 per cent in its stock price ...
- AstraZeneca Pharma NCDs get P1 ratingCRISIL has assigned ‘P1+’ rating to the short term secured fully-paid redeemable non-convertible bonus debenture issue of AstraZeneca Pharm...
Load More
